ZLAB Stock Overview
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Zai Lab Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$16.02 |
52 Week High | US$40.42 |
52 Week Low | US$15.69 |
Beta | 1.13 |
1 Month Change | -28.77% |
3 Month Change | -41.38% |
1 Year Change | -52.51% |
3 Year Change | -87.77% |
5 Year Change | -48.60% |
Change since IPO | -11.00% |
Recent News & Updates
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Recent updates
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?
May 18Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses
Mar 08Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates
Mar 06Shareholder Returns
ZLAB | US Biotechs | US Market | |
---|---|---|---|
7D | -7.1% | 0.9% | 0.2% |
1Y | -52.5% | 11.0% | 28.1% |
Return vs Industry: ZLAB underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: ZLAB underperformed the US Market which returned 28.8% over the past year.
Price Volatility
ZLAB volatility | |
---|---|
ZLAB Average Weekly Movement | 8.0% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZLAB's share price has been volatile over the past 3 months.
Volatility Over Time: ZLAB's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 2,175 | Samantha Du | https://www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
ZLAB fundamental statistics | |
---|---|
Market cap | US$1.60b |
Earnings (TTM) | -US$334.62m |
Revenue (TTM) | US$266.72m |
5.9x
P/S Ratio-4.7x
P/E RatioIs ZLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZLAB income statement (TTM) | |
---|---|
Revenue | US$266.72m |
Cost of Revenue | US$361.68m |
Gross Profit | -US$94.96m |
Other Expenses | US$239.66m |
Earnings | -US$334.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.39 |
Gross Margin | -35.60% |
Net Profit Margin | -125.46% |
Debt/Equity Ratio | 0% |
How did ZLAB perform over the long term?
See historical performance and comparison